Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade D 50.07 0.44% 0.22
RGNX closed up 4.55 percent on Thursday, July 18, 2019, on approximately normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical RGNX trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.44%
Crossed Above 20 DMA Bullish 0.44%
MACD Bullish Signal Line Cross Bullish 0.44%
Crossed Above 50 DMA Bullish 5.01%
Fell Below 50 DMA Bearish 6.62%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.62%
Inside Day Range Contraction 6.62%
Crossed Above 50 DMA Bullish 4.29%
Up 3 Days in a Row Strength 4.29%
50 DMA Resistance Bearish 5.45%

Older signals for RGNX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Medical Genetics Applied Genetics Wet Age Related Macular Degeneration Retinitis Pigmentosa Gene Delivery Adeno Associated Virus X Linked Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase
Is RGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 83.45
52 Week Low 38.56
Average Volume 567,954
200-Day Moving Average 52.4021
50-Day Moving Average 47.2862
20-Day Moving Average 48.6705
10-Day Moving Average 47.117
Average True Range 2.5432
ADX 13.07
+DI 22.2762
-DI 15.9701
Chandelier Exit (Long, 3 ATRs ) 47.6004
Chandelier Exit (Short, 3 ATRs ) 51.9896
Upper Bollinger Band 53.0969
Lower Bollinger Band 44.2441
Percent B (%b) 0.63
BandWidth 18.189252
MACD Line -0.238
MACD Signal Line -0.2774
MACD Histogram 0.0394
Fundamentals Value
Market Cap 1.54 Billion
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -18.53
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.05
Resistance 3 (R3) 53.63 51.82 53.35
Resistance 2 (R2) 51.82 50.75 52.03 53.12
Resistance 1 (R1) 50.83 50.09 51.33 51.25 52.88
Pivot Point 49.02 49.02 49.26 49.23 49.02
Support 1 (S1) 48.03 47.95 48.53 48.45 46.82
Support 2 (S2) 46.22 47.29 46.43 46.58
Support 3 (S3) 45.23 46.22 46.35
Support 4 (S4) 45.65